Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 6/2011

01-06-2011 | Leading Article

Suicidal Ideation during Antidepressant Treatment

Do Genetic Predictors Exist?

Author: Dr Nader Perroud

Published in: CNS Drugs | Issue 6/2011

Login to get access

Abstract

Suicidal thoughts during antidepressant treatment have recently been the focus of several candidate gene and genome-wide association studies. Although the clinical risk factors for such events are well known, unfortunately they do not help to predict who will have a suicidal event during antidepressant treatment and who will not. Pharmacogenomic studies have therefore attempted to use genetic variants to predict individual susceptibility to treatment-related suicidal ideation. In this perspective, several genetic predictors have been highlighted, the majority of which relate to common mechanisms of antidepressant action: genes involved in the neurotrophic and synaptic plasticity systems (CREB1, and BDNF and its receptor NTRK2), noradrenergic system (ADRA2A), glutamatergic system (GRIA3, GRIK2 and GDA), inflammatory and hypothalamic-pituitary-adrenal (HPA) axis systems (IL28RA and FKBP5) and in other brain functions (PAPLN, APOO, KCNIP4 and ELP3). Although some of these genes may be of interest in predicting antidepressant-induced suicidal ideation, they still need to be validated in better phenotypically designed samples. Several methodological factors are indeed responsible for the problems involved in implicating these findings in the causation of a clinically relevant phenotype. These include discrepancies between studies in defining phenotypes, with several different thresholds used to establish significant suicidal ideation; the use of scales not truly designed to measure suicidal ideation; and the paucity of true suicidal events (suicide attempts and/or completion) in pharmacogenomic studies.
In conclusion, pharmacogenomic studies are far from fulfilling their promise. There is a need for future pharmacogenetic studies targeting events that are clinically significant in order to find associated variants that will help clinicians to improve their treatment strategies. While awaiting these genetic predictors, clinicians need to bear in mind that all studies in this field support a beneficial effect of antidepressants on suicidal ideation. This should therefore encourage them to prescribe antidepressant medication even in patients with suicidal ideation.
Literature
1.
Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63(3): 332–9PubMedCrossRef
2.
US Food and Drug Administration. Clinical review: relationship between antidepressant drugs and suicidality in adults [online]. Available from URL: http://​www.​fda.​gov/​ [Accessed 2008 Apr 28]
3.
4.
5.
Friedman RA, Leon AC. Expanding the black box: depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356(23): 2343–6PubMedCrossRef
6.
Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164(9): 1356–63PubMedCrossRef
7.
Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 2003; 28(5): 331–7PubMed
8.
Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003; 72(2): 71–9PubMedCrossRef
9.
Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008; 69(6): 946–58PubMedCrossRef
10.
Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292(3): 338–43PubMedCrossRef
11.
Nutt DJ. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psycho-pharmacol 2003; 17(4): 355–64
12.
Perlis RH, Beasley Jr CM, Wines Jr JD, et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007; 76(1): 40–6PubMedCrossRef
13.
Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993; 8(3): 186–212PubMedCrossRef
14.
Akiskal HS, Benazzi F, Perugi G, et al. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 2005; 85(3): 245–58PubMedCrossRef
15.
Berk M, Dodd S. Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Med Hypotheses 2005; 65(1): 39–43PubMedCrossRef
16.
Harada T, Sakamoto K, Ishigooka J. Incidence and predictors of activation syndrome induced by antidepressants. Depress Anxiety 2008; 25(12): 1014–9PubMedCrossRef
17.
Culpepper L, Davidson JR, Dietrich AJ, et al. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry 2004; 65(6): 742–9PubMedCrossRef
18.
Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12(2): 192–214PubMedCrossRef
19.
20.
Baldassano CF, Truman CJ, Nierenberg A, et al. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 1996; 37(2): 122–4PubMedCrossRef
21.
Perroud N, Uher R, Marusic A, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med 2009; 7: 60PubMedCrossRef
22.
Balazs J, Benazzi F, Rihmer Z, et al. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006; 91(2-3): 133–8PubMedCrossRef
23.
Pokorny AD. Prediction of suicide in psychiatric patients: report of a prospective study. Arch Gen Psychiatry 1983; 40(3): 249–57PubMedCrossRef
24.
Goldstein RB, Black DW, Nasrallah A, et al. The prediction of suicide: sensitivity, specificity, and predictive value of a multivariate model applied to suicide among 1906 patients with affective disorders. Arch Gen Psychiatry 1991; 48(5): 418–22PubMedCrossRef
25.
van Egmond M, Diekstra RF. The predictability of suicidal behavior: the results of a meta-analysis of published studies. Crisis 1990; 11(2): 57–84PubMed
26.
Anderson RN. Deaths: leading causes for 1999. Natl Vital Stat Rep 2001;49(11): 1–87
27.
Brent DA, Mann JJ. Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C Semin Med Genet 2005; 133C(1): 13–24PubMedCrossRef
28.
Fu Q, Heath AC, Bucholz KK, et al. A twin study of genetic and environmental influences on suicidality in men. Psychol Med 2002; 32(1): 11–24PubMedCrossRef
29.
Butler AW, Breen G, Tozzi F, et al. A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. Am J Med Genet B Neuropsychiatr Genet 2010; 153B(8): 1465–73PubMedCrossRef
30.
Cui H, Supriyanto I, Asano M, et al. A common polymorphism in the 3′-UTR of the NOS1 gene was associated with completed suicides in Japanese male population. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(6): 992–6PubMedCrossRef
31.
Wang Y, Zhang J, Liu B, et al. Genetic polymorphisms in the SCN8A gene are associated with suicidal behavior in psychiatric disorders in the Chinese population. World J Biol Psychiatry 2010; 11(8): 956–63PubMedCrossRef
32.
Nedic G, Nikolac M, Sviglin KN, et al. Association study of a functional catechol-O-methyltransferase (COMT) Val108/ 158Met polymorphism and suicide attempts in patients with alcohol dependence. Int J Neuropsychopharmacol 2011; 14(3): 377–88PubMedCrossRef
33.
Zalsman G, Patya M, Frisch A, et al. Association of polymorphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: a multi-center study. World J Biol Psychiatry 2011; 12(1): 33–41PubMedCrossRef
34.
35.
Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25(1): 119–42PubMedCrossRef
36.
Uher R, Farmer A, Maier W, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008; 38(2): 289–300PubMedCrossRef
37.
Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients: findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009; 43(3): 215–29PubMedCrossRef
38.
Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299(8): 901–13PubMedCrossRef
39.
Brent D, Melhem N, Turecki G. Pharmacogenomics of suicidal events. Pharmacogenomics 2010; 11(6): 793–807PubMedCrossRef
40.
Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007; 64(6): 689–97PubMedCrossRef
41.
Laje G, Allen AS, Akula N, et al. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 2009; 19(9): 666–74PubMedCrossRef
42.
Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164(10): 1530–8PubMedCrossRef
43.
Perroud N, Aitchison KJ, Uher R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 2009; 34(12): 2517–28PubMedCrossRef
44.
Menke A, Lucae S, Kloiber S, et al. Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am J Psychiatry 2008; 165(7): 917–8PubMedCrossRef
45.
Brent D, Melhem N, Ferrell R, et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2010; 167(2): 190–7PubMedCrossRef
46.
Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord 2009; 117(1–2): 63–73PubMedCrossRef
47.
Perroud N, Uher R, Ng M, et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. Epub 2010 Sep 28
48.
Dwivedi Y, Rao JS, Rizavi HS, et al. Abnormal expression and functional characteristics of cyclic adenosine mono-phosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60(3): 273–82PubMedCrossRef
49.
Young LT, Bezchlibnyk YB, Chen B, et al. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biol Psychiatry 2004; 55(6): 570–7PubMedCrossRef
50.
Baud P, Courtet P, Perroud N, et al. Catechol-O-methyl-transferase polymorphism (COMT) in suicide attempters: a possible gender effect on anger traits. Am J Med Genet B Neuropsychiatr Genet 2007; 144B(8): 1042–7PubMedCrossRef
51.
Perlis RH, Purcell S, Fagerness J, et al. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol Psychiatry 2007; 62(5): 536–40PubMedCrossRef
52.
Palucha A, Pilc A. The involvement of glutamate in the pathophysiology of depression. Drug News Perspect 2005; 18(4): 262–8PubMedCrossRef
53.
Dwivedi Y, Rizavi HS, Conley RR, et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60(8): 804–15PubMedCrossRef
54.
Altar CA, Whitehead RE, Chen R, et al. Effects of electro-convulsiveseizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54(7): 703–9PubMedCrossRef
55.
Coppell AL, Pei Q, Zetterstrom TS. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003; 44(7): 903–10PubMedCrossRef
56.
Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 2004; 29(8): 1512–21PubMedCrossRef
57.
Wakeno M, Kato M, Okugawa G, et al. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin Psychopharmacol 2008; 28(5): 518–24PubMedCrossRef
58.
Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000; 23(1): 11–25PubMedCrossRef
59.
Ising M, Depping AM, Siebertz A, et al. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci 2008; 28(2): 389–98PubMedCrossRef
60.
Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36(12): 1319–25PubMedCrossRef
61.
Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12(3): 365–77PubMedCrossRef
62.
Mann JJ, Currier D. A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch Suicide Res 2007; 11(1): 3–16PubMedCrossRef
63.
Scammell JG, Denny WB, Valentine DL, et al. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. Gen Comp Endocrinol 2001; 124(2): 152–65PubMedCrossRef
64.
Roy A, Gorodetsky E, Yuan Q, et al. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 2010; 35(8): 1674–83PubMed
65.
Janssen HL, Brouwer JT, van der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21(2): 241–3PubMedCrossRef
66.
Akum BF, Chen M, Gunderson SI, et al. Cypin regulates dendrite patterning in hippocampal neurons by promoting microtubule assembly. Nat Neurosci 2004; 7(2): 145–52PubMedCrossRef
67.
Feyissa AM, Chandran A, Stockmeier CA, et al. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(1): 70–5PubMedCrossRef
68.
Guipponi M, Deutsch S, Kohler K, et al. Genetic and epigenetic analysis of SSAT gene dysregulation in suicidal behavior. Am J Med Genet B Neuropsychiatr Genet 2009; 150B(6): 799–807PubMedCrossRef
69.
Brown G. A review of suicide assessment measures for intervention research with adults and older adults. Philadelphia (PA): University of Pennsylvania, 2002
70.
Nock MK, Wedig MM, Janis IB, et al. Self-injurious thoughts and behaviors. In: Hunsley J, Mash EJ, editors. A guide to assessments that work. London: Oxford University Press, 2008: 158–78
71.
Range LM, Knott EC. Twenty suicide assessment instruments: evaluation and recommendations. Death Stud 1997; 21(1): 25–58PubMedCrossRef
72.
Winters NC, Myers K, Proud L. Ten-year review of rating scales: III. Scales assessing suicidality, cognitive style, and self-esteem. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1150–81
73.
Newport DJ, Levey LC, Pennell PB, et al. Suicidal ideation in pregnancy: assessment and clinical implications. Arch Womens Ment Health 2007; 10(5): 181–7PubMedCrossRef
74.
Kessler RC, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990–1992 to 2001–2003. JAMA 2005; 293(20): 2487–95PubMedCrossRef
75.
Suicidal behavior and psychotropic medication: accepted as a consensus statement by the ACNP Council, March 2, 1992. Neuropsychopharmacology 1993; 8 (2): 177-83
76.
Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development. A consensus statement. J Clin Psychiatry 2010; 71(8): e1–21PubMedCrossRef
77.
Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development. A brief report. J Clin Psychiatry 2010; 71(8): 1040–6
78.
Price AL, Kryukov GV, de Bakker PI, et al. Pooled association tests for rare variants in exon-resequencing studies. Am J Hum Genet 2010; 86(6): 832–8PubMedCrossRef
79.
Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001; 69(1): 124–37PubMedCrossRef
80.
Frazer KA, Murray SS, Schork NJ, et al. Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009; 10(4): 241–51PubMedCrossRef
81.
Iyengar SK, Elston RC. The genetic basis of complex traits: rare variants or “common gene, common disease”? Methods Mol Biol 2007; 376: 71–84PubMedCrossRef
82.
Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 2008; 83(3): 311–21PubMedCrossRef
83.
84.
Caspi A, Hariri AR, Holmes A, et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010; 167(5): 509–27PubMedCrossRef
85.
Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 2003; 100(24): 14293–6PubMedCrossRef
86.
Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010; 64(4): 341–57PubMedCrossRef
87.
Karege F, Vaudan G, Schwald M, et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005; 136(1-2): 29–37PubMedCrossRef
Metadata
Title
Suicidal Ideation during Antidepressant Treatment
Do Genetic Predictors Exist?
Author
Dr Nader Perroud
Publication date
01-06-2011
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 6/2011
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11589420-000000000-00000

Other articles of this Issue 6/2011

CNS Drugs 6/2011 Go to the issue

Current Opinion

Pharmacotherapy for Primary CNS Lymphoma

Review Article

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

Short Communication

Lower IQ is Associated with Decreased Clinical Response to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

Adis Drug Profile

Fentanyl Pectin Nasal Spray

Adis Drug Evaluation

Oral Paliperidone

Review Article

Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics